Bio-Path Holdings Inc (NASDAQ:BPTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The brokerage presently has a $0.75 price target on the stock. Zacks Investment Research’s price target would indicate a potential downside of 9.87% from the stock’s current price.

According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. “

Separately, HC Wainwright set a $5.00 price target on shares of Bio-Path Holdings and gave the stock a “buy” rating in a research report on Thursday.



Shares of Bio-Path Holdings (NASDAQ:BPTH) traded up 8.0649% during mid-day trading on Monday, hitting $0.8321. 174,606 shares of the company’s stock traded hands. The firm has a 50-day moving average of $0.87 and a 200 day moving average of $1.14. The company’s market cap is $79.59 million. Bio-Path Holdings has a 52 week low of $0.70 and a 52 week high of $3.19.

Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings results on Wednesday, March 15th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.02. Equities research analysts predict that Bio-Path Holdings will post ($0.09) EPS for the current year.

Your IP Address:

An institutional investor recently raised its position in Bio-Path Holdings stock. HighTower Advisors LLC increased its position in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,155,070 shares of the company’s stock after buying an additional 12,000 shares during the period. HighTower Advisors LLC owned 1.21% of Bio-Path Holdings worth $1,617,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

5 Day Chart for NASDAQ:BPTH

Receive News & Stock Ratings for Bio-Path Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc and related stocks with our FREE daily email newsletter.